DA-1726
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
DA-1726 is an experimental dual GLP-1/glucagon agonist studied for weight loss and liver fat reduction. The case rests on one small Phase 1 trial: weight and waist losses look promising, but glucose and liver-stiffness signals are weak, with no larger trials yet. GI effects are common, and its glucagon activity carries a theoretical risk of raising blood sugar. Not an approved drug, with no long-term safety data and only unregulated research-grade supply.
Read Full recordStudied uses & evidence
Studied uses(6)
Robust early weight loss (9.1% at 8 weeks without dose titration)
MediumSmall randomized Phase 1 trial; the 8-week extension figure lacked a placebo comparison.
Significant waist circumference reduction (9.8 cm at Day 54) suggesting visceral fat targeting
MediumPlacebo-controlled human data on waist size; visceral fat targeting is inferred, not measured directly.
Fasting glucose improvement (12.3 mg/dL from baseline of 105.3 mg/dL)
LowSingle small study, no placebo comparison reported, from a near-normal baseline glucose level.
Evidence limits
- Evidence Level
- Early Evidence (Phase 1)
DA-1726 has completed Phase 1 single and multiple ascending dose cohorts. The 48 mg non-titrated cohort showed 9.1% weight loss at 8 weeks with no serious adverse events or treatment-related discontinuations. However, only small numbers of participants have been studied (approximately 9 per cohort), and no Phase 2 or Phase 3 data are available. Phase 1 Part 3 began in April 2026; dose-titration completion was announced in July, with 16-week results expected in Q4 2026.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events (mild to moderate)
ModerateVery limited clinical data (Phase 1 only)
HighGlucagon-mediated hyperglycemia risk (theoretical)
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.